Sanofi said on August 27 that it has launched the subcutaneous formulation of its multiple myeloma therapy Sarclisa (isatuximab) in Japan, offering a shorter administration time than the existing intravenous version.Sarclisa SC Injection 1400 mg is indicated for multiple myeloma…
To read the full story
Related Article
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
BUSINESS
- Japan Approves Fuji’s New Stelara, Simponi Biosimilar Formulations
September 17, 2026
- Nobelpharma, Fuso to Co-Promote Hypozincemia Drug Zintus
September 17, 2026
- Sanofi Japan Targets AI Fluency across Workforce by End-2027
September 16, 2026
- Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
- JCR Outside Director Fauchet Steps Down
September 16, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





